Related Experiment Video
Updated: May 3, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Novel hypoglycaemic agents: considerations in patients with chronic kidney disease
1Department of Diabetes and Endocrinology, Derby Hospitals NHS FT, Derby, UK.
Abstract:
One of the commonest complications of type 2 diabetes is renal disease. Treatment guidelines emphasise the need for tight glycaemic control to reduce the development of future complications; however, with the development of renal impairment, the benefit of tight glycaemic control must be weighed against the potential for adverse effects from drugs or their metabolites which may accumulate. In this article, the glucose-lowering drugs used in the management of type 2 diabetes are reviewed, with particular emphasis on newer guidelines and agents.
Insights
Managing type 2 diabetes with kidney disease requires careful glucose control. Newer guidelines and agents help balance blood sugar targets with potential drug side effects in patients with renal impairment.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Diabetic kidney disease is a common complication of type 2 diabetes.
- Tight glycemic control is recommended to prevent diabetes complications.
- Renal impairment necessitates careful consideration of drug efficacy and safety due to potential metabolite accumulation.
Purpose of the Study:
- To review glucose-lowering drugs for type 2 diabetes management.
- To emphasize updated guidelines and newer agents.
- To address the challenges of glycemic control in patients with renal impairment.
Main Methods:
- Literature review of current treatment guidelines.
- Analysis of pharmacokinetic and pharmacodynamic properties of glucose-lowering agents.
- Evaluation of safety profiles in patients with varying degrees of renal function.
Main Results:
- Specific glucose-lowering drugs require dose adjustment or avoidance in renal impairment.
- Newer agents may offer improved safety profiles or alternative mechanisms of action.
- Balancing glycemic targets with renal function is crucial for optimal patient outcomes.
Conclusions:
- Treatment decisions for type 2 diabetes with renal disease must be individualized.
- Clinicians should be aware of drug accumulation risks and adjust therapy accordingly.
- Ongoing research into safer and more effective glucose-lowering strategies for renally impaired patients is essential.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Diabetic Nephropathy
Chronic Kidney Disease I: Introduction
Oral Hypoglycemic Agents: Glinides
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease IV: Nursing Management

